网友提问:
海普瑞(002399)
SLIDE 1So welcome to the annual meeting and as I said the weather seems to track us for this, I don’t know why, but it does.SLIDE 2We have a forward looking statement as usualSLIDE 3And this is Resverlogix at a glance.We are a late-stage clinical biotechnology company with a leadership position in epigeneticsAnd that is starting to be recognized globally, so we’re pretty excited about that. Our lead product is Apabetalone, a first-in-class small molecule – we have about a ten year lead on anybody else, so. We have broad applications in cardiovascular, renal, and other disease indications, some
网友回复
自然味道18:
不是
promiscs4459:
发表于 2018-10-1020:51:07SLIDE 6
So just the investment highlights.
We are a global leader in this area and are being well recognized for it at this stage.
As you probably know, all others in the BET bromodomain space are in oncology only
because they don’t have as full a grasp of the biology as we do.
Apabetalone is a f...
promiscs4459:
发表于 2018-10-1020:51:23SLIDE 7
So addressing the unmet needs in the cardiovascular side
Where we’ve really focused over the years is this sixty to seventy percent unmet need
You know the thirty percent is taken care of by the statins.
Some of these newer drugs, the PCSK9s and some of the LDL modulators,
they’ll take up ab...
promiscs4459:
发表于 2018-10-1020:52:34So I’ll used inflammation markers as an example.
The inflammation markers get turned on and the body cranks up the inflammation marker proteins.
Well what happens then they keep replicating saying more more and more
So you have this domino effect and it just keeps creating more inflammation markers,...
promiscs4459:
发表于 2018-10-1020:53:27SLIDE 11
Now in learning about all of this, we actually in part of that reverse engineering that I was explaining, we went in and we learned a lot of stuff, particularly the main pathways in which this drug works in a cardiovascular patient.
So we started with reverse cholesterol transport, and that...
promiscs4459:
发表于 2018-10-1020:54:19SLIDE 14
OK let’s go on here.
So we designed the BET on MACE trial based on that information.
And we were very selective about the patients, because we wanted the sickest patient group.
We wanted patients who had diabetes, who’ve had a major even in 7 to 90 days, and who have low HDL. The reason for...
promiscs4459:
发表于 2018-10-1020:56:40and then you can make a decision do you keep enrolling or whatever
But now that you haven’t been enrolling for eight months, well if I put more patients in now,
I’ve got to leave them in at least six months, so that means this trial is going to the end of 2019.
And I don’t think any of us want that....
promiscs4459:
谷歌翻了下,RVX进展的很顺利的,目标市场很大,目前已经有药物占30%市场有140亿美金,专利期2034年
自然味道18:
我也是翻译软件哈。很好奇这内容哪里来的链接?
自然味道18:
我也是翻译软件哈!很好奇内容是哪里来的链接?
听涛深圳湾:
十分感谢楼主分享的资料,实在太好了,令人印象深刻!
楼主是何方高人可以弄到这个资料?佩服。
听涛深圳湾:
是Resverlogix年度股东大会上的资料吗?
混走萝:
兄弟比较厉害
promiscs4459:
是的
promiscs4459:
东财一次只能发一点点
听涛深圳湾:
这样吧,如果股吧里诸位股友认为有需要,我将在周末将楼主提供的资料逐条给出概要翻译,也就是将该资料的主要意思用中文表达出来。
自然味道18:
赞!